NCT06988865Completed
Benign Migratory Glossitis Associated With Antiangiogenic Drugs
Benign Migratory Glossitis Associated With Antiangiogenic Drugs Used in Cancer Treatment
Source: ClinicalTrials.gov · Last updated 25 May 2025
Brief summary (registry, in English)
Oral clinical descriptions related to adverse events in patients treated with those elective multi-targeted receptor tyrosine kinase inhibitors and a recombinant humanised monoclonal antibody
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 8 (actual)
- First submitted
- 1 May 2025
- Start date
- 16 Jul 2017
- Primary completion date
- 10 Jan 2020
- Lead sponsor
- Instituto do Cancer do Estado de São Paulo
- Diseases
- Childhood cancers
- NCT number
- NCT06988865
What you commit to
- Study type: Observational
- Participants enrolled: 8
- From 16 Jul 2017 to the primary completion date, 10 Jan 2020
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- chemoterapy without angiogenesis inhibitors
Who the study is looking for
- patient's charts which underwent antiangiogenic targeted drugs
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Instituto do Câncer do Estado de São Paulo Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.